quinacrine has been researched along with Breast Neoplasms in 27 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinacrine (QC) causes apoptosis in breast cancer cells by induction of DNA damage, arrest of cells in S-phase, and by topoisomerase inhibition." | 7.83 | Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. ( Das, D; Das, S; Kundu, CN; Nayak, A; Preet, R; Satapathy, SR; Siddharth, S; Wyatt, MD, 2016) |
| "We previously reported that quinacrine (QC) has anticancer activity against breast cancer cells." | 7.79 | Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. ( Choudhuri, T; Das, D; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Wyatt, MD, 2013) |
| "Twenty-five patients with malignant pleural effusion were treated with a single intrapleural dose of Quinacrine." | 7.65 | Quinacrine in the management of malignant pleural effusion. ( Hooton, NS; Macarthur, AM; Taylor, SA, 1977) |
| "This cell line of breast cancer expresses the triple negative characteristics." | 5.56 | Effects of Quinacrine on Expression of Hippo signaling Pathway Components (LATS1, LATS2, and YAP) in Human Breast Cancer Stem Cells. ( Asadolahi, M; Darbankhales, S; Darbeheshti, S; Ganjkhanlou, Z; Ghahremani, H; Mirfakhraie, R; Safakish, L; Saket-Kisomi, K; Salami, S; Sirati-Sabet, M, 2020) |
| "Multiple breast cancer-derived cell lines (MCF-7, ZR-75-1, T47D, MDA-MB-231 and MCF-10A-Tr) and a mouse xenograft model were used." | 5.46 | TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions. ( Das, S; Kundu, CN; Narayan, S; Nayak, A; Nayak, D; Siddharth, S, 2017) |
| "Recurrence of invasive breast cancer could arise from the residual cancer cells after comprehensive treatment." | 5.42 | Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. ( Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y, 2015) |
| " Here, we have precisely evaluated the mechanism of PARP trapping mediated anti-cancer action of Quinacrine (QC), BMN-673, and their combination (QC + BMN-673) in breast cancer cells." | 4.12 | PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells. ( Kundu, CN; Sethy, C, 2022) |
| "Quinacrine (QC) causes apoptosis in breast cancer cells by induction of DNA damage, arrest of cells in S-phase, and by topoisomerase inhibition." | 3.83 | Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. ( Das, D; Das, S; Kundu, CN; Nayak, A; Preet, R; Satapathy, SR; Siddharth, S; Wyatt, MD, 2016) |
| "We previously reported that quinacrine (QC) has anticancer activity against breast cancer cells." | 3.79 | Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. ( Choudhuri, T; Das, D; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Wyatt, MD, 2013) |
| "Twenty-five patients with malignant pleural effusion were treated with a single intrapleural dose of Quinacrine." | 3.65 | Quinacrine in the management of malignant pleural effusion. ( Hooton, NS; Macarthur, AM; Taylor, SA, 1977) |
| "This cell line of breast cancer expresses the triple negative characteristics." | 1.56 | Effects of Quinacrine on Expression of Hippo signaling Pathway Components (LATS1, LATS2, and YAP) in Human Breast Cancer Stem Cells. ( Asadolahi, M; Darbankhales, S; Darbeheshti, S; Ganjkhanlou, Z; Ghahremani, H; Mirfakhraie, R; Safakish, L; Saket-Kisomi, K; Salami, S; Sirati-Sabet, M, 2020) |
| "Multiple breast cancer-derived cell lines (MCF-7, ZR-75-1, T47D, MDA-MB-231 and MCF-10A-Tr) and a mouse xenograft model were used." | 1.46 | TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions. ( Das, S; Kundu, CN; Narayan, S; Nayak, A; Nayak, D; Siddharth, S, 2017) |
| "Recurrence of invasive breast cancer could arise from the residual cancer cells after comprehensive treatment." | 1.42 | Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. ( Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y, 2015) |
| "Cohort study." | 1.31 | Cancer risk among women sterilized with transcervical quinacrine in Chile: an update through 1996. ( Dabancens, A; Guzman-Serani, R; Sokal, DC; Zipper, J, 2000) |
| "Pleural effusion secondary to breast cancer is a locoregional manifestation." | 1.29 | Pleural effusion in breast cancer: a review of the Nottingham experience. ( Banerjee, AK; Blamey, RW; Robertson, JF; Willetts, I, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (37.04) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Solomon, VR | 1 |
| Pundir, S | 1 |
| Le, HT | 1 |
| Lee, H | 1 |
| Sethy, C | 1 |
| Kundu, CN | 6 |
| Das, B | 1 |
| Dash, SR | 1 |
| Patel, H | 1 |
| Sinha, S | 1 |
| Bhal, S | 1 |
| Paul, S | 1 |
| Das, C | 1 |
| Pradhan, R | 1 |
| Ahmed, I | 1 |
| Goutam, K | 1 |
| Nayak, D | 2 |
| Tripathi, N | 1 |
| Kathuria, D | 1 |
| Siddharth, S | 3 |
| Nayak, A | 3 |
| Bharatam, PV | 1 |
| Kundu, C | 1 |
| Darbankhales, S | 1 |
| Mirfakhraie, R | 1 |
| Ghahremani, H | 1 |
| Asadolahi, M | 1 |
| Saket-Kisomi, K | 1 |
| Safakish, L | 1 |
| Darbeheshti, S | 1 |
| Ganjkhanlou, Z | 1 |
| Salami, S | 1 |
| Sirati-Sabet, M | 1 |
| Samanta, A | 1 |
| Sarkar, A | 1 |
| Das, S | 2 |
| Narayan, S | 1 |
| Sun, MG | 2 |
| Shi, JF | 2 |
| Li, XY | 1 |
| Zhao, Y | 1 |
| Ju, RJ | 2 |
| Mu, LM | 1 |
| Yan, Y | 1 |
| Li, XT | 1 |
| Zeng, F | 1 |
| Lu, WL | 2 |
| Preet, R | 3 |
| Satapathy, SR | 2 |
| Das, D | 2 |
| Wyatt, MD | 3 |
| Mohapatra, P | 2 |
| Mohanty, S | 1 |
| Sahu, SK | 1 |
| Choudhuri, T | 2 |
| Zhang, L | 1 |
| Yao, HJ | 1 |
| Yu, Y | 1 |
| Zhang, Y | 1 |
| Li, RJ | 1 |
| Wang, XX | 1 |
| ROCHLIN, DB | 1 |
| SMART, CR | 1 |
| WAGNER, DE | 1 |
| SILVA, AR | 1 |
| Thomas, W | 1 |
| Coen, N | 1 |
| Faherty, S | 1 |
| Flatharta, CO | 1 |
| Harvey, BJ | 1 |
| Borda, I | 1 |
| Krant, M | 1 |
| Kivi, S | 1 |
| Mikelsaar, AV | 1 |
| Jäättelä, M | 1 |
| Benedict, M | 1 |
| Tewari, M | 1 |
| Shayman, JA | 1 |
| Dixit, VM | 1 |
| Banerjee, AK | 1 |
| Willetts, I | 1 |
| Robertson, JF | 1 |
| Blamey, RW | 1 |
| Sokal, DC | 1 |
| Dabancens, A | 1 |
| Guzman-Serani, R | 1 |
| Zipper, J | 1 |
| Johnson, LP | 1 |
| Rivkin, SE | 1 |
| Weber, EL | 1 |
| Taylor, SA | 1 |
| Hooton, NS | 1 |
| Macarthur, AM | 1 |
| Shiiki, S | 1 |
| Fuchimoto, S | 1 |
| Orita, K | 1 |
| Kreuser, ED | 1 |
| Smith, FE | 1 |
| Lane, M | 1 |
| Hudgins, PT | 1 |
| Hiller, RI | 1 |
| Farber, LR | 1 |
| Hickman, JA | 1 |
| Jones, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab[NCT03167268] | Phase 2 | 28 participants (Actual) | Interventional | 2016-08-03 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for quinacrine and Breast Neoplasms
| Article | Year |
|---|---|
[Malignant pleural effusions. Pathophysiology, diagnosis and therapy].
Topics: Absorption; Amylases; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Capillary Permea | 1985 |
26 other studies available for quinacrine and Breast Neoplasms
| Article | Year |
|---|---|
Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2018 |
PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Chromatin; DNA Damage; DNA Repair; Female; Flap | 2022 |
Quinacrine inhibits HIF-1α/VEGF-A mediated angiogenesis by disrupting the interaction between cMET and ABCG2 in patient-derived breast cancer stem cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Cell Line, Tumor | 2023 |
Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2020 |
Effects of Quinacrine on Expression of Hippo signaling Pathway Components (LATS1, LATS2, and YAP) in Human Breast Cancer Stem Cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Proteins; Cell Pro | 2020 |
Altered expression of ERK, Cytochrome-c, and HSP70 triggers apoptosis in Quinacrine-exposed human invasive ductal carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Ductal; Cell Line, Tumor; Cell Surviv | 2021 |
TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.
Topics: Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Humans; Quinacrine; Reactiv | 2017 |
Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Epirubi | 2015 |
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Checkpoint Kinase 1; DNA Repair; Drug | 2016 |
Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity.
Topics: Adult; Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle; | 2012 |
Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspase 9; Cell Line, T | 2012 |
Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC.
Topics: Adenomatous Polyposis Coli Protein; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apop | 2013 |
THE CONTROL OF RECURRENT MALIGNANT EFFUSIONS USING QUINACRINE HYDROCHLORIDE.
Topics: Ascites; Biomedical Research; Breast Neoplasms; Central Nervous System Diseases; Colonic Neoplasms; | 1964 |
Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Calcium; Cattle; Cyclooxygenase Inhibitors; Enzyme | 2006 |
Convulsions following intrapleural administration of quinacrine hydrochloride.
Topics: Adult; Breast Neoplasms; Epilepsy; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm | 1967 |
Q- and C-band polymorphisms in patients with ovarian or breast carcinoma.
Topics: Adult; Aged; Azure Stains; Breast Neoplasms; Carcinoma; Chromosome Banding; Chromosomes, Human; Fema | 1980 |
Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells.
Topics: Antigens, Surface; Apoptosis; Base Sequence; bcl-X Protein; Breast Neoplasms; Cell Division; Ceramid | 1995 |
Pleural effusion in breast cancer: a review of the Nottingham experience.
Topics: Adult; Aged; Breast Neoplasms; Chest Tubes; Female; Humans; Instillation, Drug; Middle Aged; Pleural | 1994 |
Cancer risk among women sterilized with transcervical quinacrine in Chile: an update through 1996.
Topics: Adult; Breast Neoplasms; Cervix Uteri; Cohort Studies; Female; Follow-Up Studies; Humans; Neoplasms; | 2000 |
Palliation in malignant pleural effusion.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drainage; Female; Hodgkin Disease; Humans; Lung Neopl | 1975 |
Quinacrine in the management of malignant pleural effusion.
Topics: Breast Neoplasms; Bronchial Neoplasms; Female; Humans; Pleural Effusion; Pleural Neoplasms; Quinacri | 1977 |
A comparison of the antitumor effects of natural human tumor necrosis factors alpha and beta: the roles of arachidonic acid metabolism and intracellular cAMP.
Topics: Arachidonic Acid; Arachidonic Acids; Breast Neoplasms; Colforsin; Colonic Neoplasms; Cyclic AMP; Dex | 1990 |
Conservative management of malignant pericardial effusion.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cardiomegaly; Female; Fluorouracil; Follow-Up Studies | 1974 |
A study of quinacrine dihyochloride in the human breast in vitro and in vivo.
Topics: Antineoplastic Agents; Biopsy; Breast; Breast Diseases; Breast Neoplasms; Cell Nucleolus; Cell Nucle | 1970 |
Correctable complications of neoplastic disease. 3. Neoplastic effusions.
Topics: Alkylating Agents; Ascitic Fluid; Breast Neoplasms; Drainage; Exudates and Transudates; Female; Huma | 1971 |
Treatment of neoplastic pleural effusions with local instillations of quinacrine (mepacrine) hydrochloride.
Topics: Adult; Aged; Breast Neoplasms; Bronchial Neoplasms; Female; Hodgkin Disease; Humans; Male; Middle Ag | 1970 |